Zobrazeno 21 - 30
of 109
pro vyhledávání: '"Andrew Haydon"'
Autor:
Michelle Frances Morris, Andrea Harkin, Martin R. Stockler, Eva Segelov, Timothy Iveson, Christine Aiken, Niall C. Tebbutt, Prunella Blinman, David Boadle, Andrew Haydon, Andrew J. Martin, David Goldstein, Michael Jefford
Publikováno v:
JNCI Cancer Spectrum
Background SCOT was an international, randomized phase 3 trial of 3 months vs 6 months of adjuvant chemotherapy with oxaliplatin and a fluoropyrimidine in patients with colorectal cancer. We sought patients’ preferences for 3 months vs 6 months of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69ec577da178882f0af2cfb5e452f04c
Autor:
Cristian Tomasetti, Dusan Kotasek, Bert Vogelstein, Craig Underhill, Suzanne Kosmider, Julian Choi, Peter Gibbs, Adrian Fox, Wei Hong, Yuxuan Wang, Hui-Li Wong, Jeanne Tie, Christos S Karapetis, Niall C. Tebbutt, Joy Schaeffer, Benjamin N. J. Thomson, Lu Li, Andrew Haydon, Matthew Burge, Joshua D. Cohen, Jenny Shannon, Janine Ptak, Michael Christie, Kenneth W. Kinzler, Kathryn M. Field, Nicholas Papadopoulos, Rachel Wong
Publikováno v:
PLoS Medicine
PLoS Medicine, Vol 18, Iss 5, p e1003620 (2021)
PLoS Medicine, Vol 18, Iss 5, p e1003620 (2021)
Background In patients with resectable colorectal liver metastases (CRLM), the role of pre- and postoperative systemic therapy continues to be debated. Previous studies have shown that circulating tumor DNA (ctDNA) analysis, as a marker of minimal re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffca5f1804285e3c3daa386a9dc7debe
Autor:
Matteo S. Carlino, Andrew Haydon, Afaf Abed, Prachi Bhave, Megan Lyle, Victoria Atkinson, Georgina V. Long, Muhammad A. Khattak, Rebecca N. Johnson, Alison Weppler, Shahneen Sandhu, Alexander M. Menzies, Geoffrey David Peters
9571 Background: Adjuvant anti-PD1 therapy reduces the risk of recurrence in resected stage III/IV melanoma and is now standard care. Limited data exist beyond registration trials. We sought to explore the use of adjuvant immunotherapy in routine cli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c39ca338aa6c845c716fe6aa79ffb2e
https://hdl.handle.net/2123/25652
https://hdl.handle.net/2123/25652
Autor:
Katy K. Tsai, Ines Pires da Silva, Andrew Haydon, Rebecca A. Burrell, Adriana Hepner, Serigne Lo, Oliver Klein, James Larkin, Matteo S. Carlino, Megan Lyle, Camille L. Gerard, Alexander M. Menzies, Lisa Zimmer, Lalit Pallan, Victoria Atkinson, Georgina V. Long, Prachi Bhave, Douglas B. Johnson, Olivier Michielin
Publikováno v:
European journal of cancer (Oxford, England : 1990). 153
Purpose Combination immunotherapy with nivolumab and ipilimumab has a high initial response rate in advanced melanoma; however, up to 55% of patients later progress. The efficacy and safety of ipilimumab re-induction in the setting of acquired resist
Autor:
Marisa Palmeri, Amelia Sawyers, Suthee Rapisuwon, Hui Yeohc, Rebecca N. Johnson, Matteo S. Carlino, Douglas B. Johnson, Alexander M. Menzies, Ryan J. Sullivan, Iman Osman, Andrew Haydon, James R. Patrinely, Maya Dimitrova, Elizabeth J. Davis, Aleigha Lawless, Prachi Bhave, Georgina V. Long, Janice M. Mehnert
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Anti-programmed death-1 (anti-PD-1) therapies have improved long-term survival across many advanced cancers. However, chronic immune-related adverse events (irAEs) are not well-defined. We sought to determine the incidence, time-course, sp
Autor:
Christopher Stuart Baker, Jack Lee, Tom Van Hagen, Victoria Atkinson, Bernard A. Fox, Carmen Ballesteros-Merino, Eric D. Whitman, Kellie Malloy Foerter, Reneta Hermiz, Sajeve Thomas, Scott J. Diede, Elizabeth Buchbinder, Katy K. Tsai, Catalin Mihalcioiu, Shawn M. Jensen, Rachel Roberts-Thomson, Sandra Aung, David A. Canton, Alain Algazi, Christopher G. Twitty, Mecker G. Möller, Clemens Krepler, Donna Bannavong, Emmett V. Schmidt, Marcus O. Butler, John R. Hyngstrom, Erica Browning, Jon Salazar, M. Shaheen, Adil Daud, Matteo S. Carlino, Andrew Mant, C. Lance Cowey, Gregory A. Daniels, Lauren Svenson, Pablo Fernandez-Penas, Igor Puzanov, Jendy Sell, Andrew Haydon
Publikováno v:
Late-breaking abstracts.
Background Electroporated plasmid IL-12 (TAVO or tavokinogene telseplasmid) is a novel pro-inflammatory intratumoral therapy with substantial single agent activity in melanoma, which has been shown to synergize with anti-PD-1 antibodies in patients p
Autor:
Evangeline Samuel, Mark Shackleton, Sagun Parakh, Paul Mitchell, Gabrielle Lie, Mark Voskoboynik, Adithya Balasubramanian, Thomas John, Ben Markman, Peter Briggs, Andrew Haydon, Maggie Moore, Alison Hiong, Yeojeong So
Publikováno v:
Clinical lung cancer. 22(3)
Background The impact of radiotherapy (RT) on the efficacy and toxicity of immune checkpoint inhibitors (ICIs) in patients with metastatic non–small-cell lung cancer (NSCLC) is unclear. Materials and Methods We identified patients with metastatic N
Autor:
Mark Nelson, John J McNeil, Peter Gibbs, Jeremy Millar, Brenda Kirpach, Ellen Richmond, Kathlyn J. Ronaldson, Asad Umar, Raj C. Shah, G J. Van Londen, Andrew Haydon, Leslie G. Ford, Christopher M. Reid, Galina Polekhina, Jeanne Tie, Jessica E. Lockery, Wendy B. Bernstein, Andrew T. Chan, Rory Wolfe, John Zalcberg, Suzanne G Orchard, L.M. Rodriguez, Anne M. Murray, Yin Cao, Catriona McLean, Robyn L. Woods, Finlay A. Macrae
Publikováno v:
Journal of the National Cancer Institute. 113(3)
Background ASPirin in Reducing Events in the Elderly, a randomized, double-blind, placebo-controlled trial of daily low-dose aspirin (100 mg) in older adults, showed an increase in all-cause mortality, primarily due to cancer. In contrast, prior rand
Autor:
Dirk Schadendorf, Caroline Dutriaux, Caroline Robert, Reinhard Dummer, John M. Kirkwood, Marta Nyakas, Mario Mandalà, Laurent Mortier, Axel Hauschild, Kohinoor Dasgupta, Monique Tan, Eduard Gasal, James Larkin, Jacob Schachter, Vanna Chiarion Sileni, Andrew Haydon, Victoria Atkinson, Mario Santinami, Georgina V. Long
10001 Background: Previous results of the COMBI-AD trial (NCT01682083) showed a significant relapse-free survival (RFS) benefit with 12 mo of adjuvant D+T vs placebo (PBO) in pts with high-risk resected stage III BRAF V600E/K–mutant melanoma. In th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f486f97df79593e3e9abb490624153c0
Autor:
Ian Porter, Trevor Leong, Paul Burton, Marty Smith, John Spillane, Mehrdad Nikfarjam, Michael W Hii, John J McNeil, John Zalcberg, Brett Knowles, Andrew Haydon, Susan E. Evans, Paul Cashin, Lara Lipton, Neil D. Merrett, James G. Kench, Peter Tagkalidis, Cuong Duong, Ashika D. Maharaj, Ri Scarborough, Liane Ioannou, Jennifer Philip, Charles H.C. Pilgrim, Peter Evans, Michael Michael, Rachel E. Neale, Julie Chu, David Goldstein, Ahmad Aly, J. Holland, Wendy A. Brown, Daniel Croagh
Publikováno v:
BMJ Open
PurposeThe Upper Gastrointestinal Cancer Registry (UGICR) was developed to monitor and improve the quality of care provided to patients with upper gastrointestinal cancers in Australia.ParticipantsIt supports four cancer modules: pancreatic, oesophag